Health TrialsbyHealthPanel

TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO

ConditionsLung Cancer, Non-small CellSmall Cell Lung CancerPleural Mesothelioma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity College, London

About this trial

TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Written Informed consent

Agreement to be followed up (including on-study assessments and sample collection) every 3 months in the first 2 years and then 6 monthly.

Agreement to be followed up at a TRACERx EVO site

Participants ≥18 years of age, with early stage I-IIIB NSCLC disease who are eligible for primary surgery

Disqualifiers

Any other active or current malignancy and/or systemic treatment (excluding hormone therapy) for that malignancy in the last 12 months (i.e., participant must be cancer free for the last 12 months, and if on therapy it can only be hormone therapy).

Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer, or for Cohort C, cases of NSCLC that have transformed to SCLC, or for Cohort A another synchronous lung cancer.

Psychological condition that would preclude informed consent

Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy

Trial population

I-IIIC or de novo metastatic (stage IV) Non-small cell lung cancer, stage I-IV Small cell lung cancer, pleural mesothelioma.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

600 Participants
are grouped into 3 trial groups
Group A: Cohort A
Group B: Cohort B
Group C: Cohort C

Trial outcomes

Primary outcomes

1

Disease Free Survival

DFS; recurrence or death from any cause): Cohorts A \& C

Time frame
5 years
2

Progression Free Survival

PFS; first disease progression or death from any cause): Cohorts B \& C

Time frame
5 years
3

Overall Survival

Time frame
5 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University College, London

Lead sponsor

Cancer Research UK

Collaborator

Source ClinicalTrials.gov
Apply now